Upstream Bio (UPB) risk factors
Item 1A of every Upstream Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors93 risks9 new5 dropped19 reworded
Upstream Bio added several new risk factors relating to its sole product candidate verekitug, clinical development funding, intellectual property, and tax law changes.
Filed Mar 26, 2026 - FY2024 10-K risk factors89 risks
Upstream Bio relies entirely on the clinical and commercial success of its sole product candidate, verekitug, targeting inflammatory diseases. Substantial ongoing losses require significant future capital raises, risking equity dilution or partnership constraints. Development depends heavily on third-party manufacturers, clinical data accuracy, and favorable regulatory approvals in multiple global jurisdictions.
Filed Mar 12, 2025